Definium Therapeutics (DFTX) vs Regencell Bioscience (RGC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Definium Therapeutics (DFTX) has outperformed Regencell Bioscience (RGC) over the past year, gaining 193.1% versus a loss of 64.5%. Over five years, RGC leads with a +1349.5% price change compared with -0.5% for DFTX.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DFTX | RGC |
|---|---|---|
| Share price | $32.92 | $7.72 |
| Market cap | $4.42B | — |
| 1-day change | -6.18% | +8.51% |
| YTD return | +162.06% | -66.14% |
| 1-year return | +193.15% | -64.54% |
| 5-year return | -0.45% | +1349.54% |
| EPS (TTM) | $-3.43 | $-0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-183.79M | $-11.70M |
| 52-week high | $49.70 | $69.00 |
| 52-week low | $10.47 | $4.51 |
| Distance from 52-week high | -33.76% | -88.82% |
| Analyst consensus | none | — |
| Avg. price target upside | +117.65% | — |
| Average volume | 2.14M | 205.08K |
| Shares outstanding | 134.37M | — |
| Employees | 105 | 10 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DFTX has outperformed RGC by 257.7 percentage points over the past year.
About Definium Therapeutics
DFTX stock →Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder.
Health Care · Medicinal Chemicals and Botanical Products · 105 employees
About Regencell Bioscience
RGC stock →Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder.
Health Care · Medicinal Chemicals and Botanical Products · 10 employees
DFTX vs RGC FAQ
Which stock has performed better over the past year, DFTX or RGC?
DFTX returned +193.15% over the past 12 months, compared with -64.54% for RGC (price return, excluding dividends). Past performance does not predict future results.
Are Definium Therapeutics and Regencell Bioscience in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.